NORTH CHICAGO, IL, USA I August 21, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the second of two pivotal studies of the Phase 3 ...

SL-325 is a potentially first-in-class DR3 antagonist antibody being developed for the treatment of Inflammatory Bowel Disease (IBD) and other ...

REYKJAVIK, Iceland and LONDON, UK I August 21, 2025 I Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of ...

MELBOURNE, Australia I August 21, 2025 I SMSbiotech, a San Diego–based leader in regenerative medicine, today announced the initiation of its first-in-human ...

SANTA MONICA, CA & PHILADELPHIA, PA, USA I August 21, 2025 I Kite, a Gilead Company (Nasdaq: GILD), today announced that it has entered into a definitive ...

An imaging-based analysis of animals treated with ExoPTEN after a spinal cord injury showed more organized spinal cord tissue ...

CRANBURY, NJ, USA I, 2025 I Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a ...

CAMBRIDGE, MA, USA I, 2025 I Larkspur Biosciences, a company pioneering a new wave in cancer therapy that destroys tumors by targeting cancer cell fitness, today announced the discovery of LRK-4189, a ...

CONSHOHOCKEN, PA, USA I August 19, 2025 I Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics ...

Company’s second clinical-stage asset licensed from Mereo Biopharma based on novel insights generated in a mouse model of osteopetrosis - ...

inMMyCAR is a multi-center Phase 1, open-label, dose-escalation clinical trial designed to assess the safety and preliminary efficacy of a single dose of KLN-1010. The first patient was dosed at Royal ...

SHANGHAI, China I August 19, 2025 I Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its self-developed ...